Soframycin Maker Encube Ethicals Seeks ₹3,000 Cr in Upcoming Public Issue.
Mumbai-based Encube Ethicals has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) to launch a public offer through an entirely Offer for Sale (OFS) amounting to up to INR 3,000 crore. Leading financial firms JM Financial, Axis Capital, and Kotak Mahindra Capital are serving as the book-running lead managers for this IPO. The company operates in the pharmaceutical sector, specializing in technically complex topical and transdermal dosage forms, and has established a robust international presence, serving 50 countries as of March 2026, driven by its three primary business segments: Global Generics, Global Contract Development and Manufacturing Organization (CDMO), and India Branded Formulations.
Encube Ethicals has demonstrated impressive financial performance, highlighted by significant top-line growth and expanding profit margins. In FY26, the company reported revenue from operations of INR 1,848.70 crore, marking a robust year-on-year increase of 37.47%. The EBITDA margins also improved considerably, rising to 35.88%, while the profit after tax margin expanded to 23.62%. Such performance metrics are indicative of the company’s operational efficiency and its ability to generate healthy returns, as evidenced by an ROE of 25.65% and ROCE of 32.30% in FY26. Grey market sentiment has been cautiously optimistic, with some analysts suggesting a positive outlook for the IPO due to the company’s growing presence in the US topical generics market.
For Indian investors, the Encube Ethicals IPO represents a compelling opportunity, particularly given the company’s strategic positioning in the global pharmaceuticals landscape. With its notable achievements, including being the third-largest player in the US topical generics market and a strong pipeline of ANDAs, investors may find value in its growth trajectory. However, it is crucial for investors to consider the potential risks associated with the company’s geographic revenue concentration, supply chain dependencies, and ongoing legal scrutiny. Thorough due diligence and consideration of these factors will be essential for investors looking to participate in this IPO, as the broader outlook for the Indian IPO market remains promising.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova IPO team.)